As noted above, under licensed use,<unk>  is also now considered to be contraindicated for the treatment of certain sexually transmitted diseases by some experts due to bacterial resistance.<unk>  is contraindicated in those with a history of tendonitis, tendon rupture and those with a hypersensitivity to fluoroquinolones. There are three contraindications found within the 2008 package insert: *"Noroxin<unk>  is contraindicated in persons with a history of hypersensitivity, tendinitis, or tendon rupture associated with the use of<unk>  or any member of the quinolone group of antimicrobial agents." *"Quinolones, including<unk> , have been shown in vitro to inhibit CYP1A2. Concomitant use with drugs metabolized by CYP1A2 (e.g., caffeine, clozapine, ropinirole, tacrine, theophylline, tizanidine) may result in increased substrate drug concentrations when given in usual doses. Patients taking any of these drugs concomitantly with<unk>  should be carefully monitored." *"Concomitant administration with tizanidine is contraindicated"<unk>  is also considered to be contraindicated within the pediatric population. *Pregnancy<unk>  has been reported to rapidly cross the blood-placenta and blood-milk barrier, and is extensively distributed into the fetal tissues. For this reason<unk>  and other fluoroquinolones are contraindicated during pregnancy due to the risk of spontaneous abortions and birth defects. The fluoroquinolones have also been reported as being present in the mother's milk and are passed on to the nursing child, which may increases the risk of the child suffering an adverse reaction even though the child had never been prescribed or taken any of the drugs found within this class. As safer alternatives are generally available<unk>  is contraindicated during pregnancy, especially during the first trimester. The manufacturer only recommends use of<unk>  during pregnancy when benefit outweighs risk. *Children A 1998 retrospective survey found that numerous side effects have been recorded in reference to the unapproved use of<unk>  in the pediatric population. Fluoroquinolones are not licensed by the FDA for use in children due to the risk of fatalities as well as permanent injury to the musculoskeletal system, with two exceptions. Ciprofloxacin is being licensed for the treatment of Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli and Inhalational Anthrax (post-exposure) and levofloxacin was recently licensed for the treatment of Inhalational Anthrax (post-exposure). However, the Fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.
Norfloxacin
Ofloxacin
Sparfloxacin
Enrofloxacin
Ciprofloxacin
Meropenem
Metronidazole
Cethromycin